Diffuse Large B-Cell Lymphoma (DLBCL): An Overview and Insight
[vc_row][vc_column][vc_custom_heading text="Diffuse Large B-Cell Lymphoma (DLBCL): An Overview and Insight" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row ...
Symptoms and Risk Factors of Atrial Fibrillation (AF)
[vc_row][vc_column][vc_custom_heading text="Symptoms and Risk Factors of Atrial Fibrillation (AF)" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc_colu ...
Avenge Bio’s AVB-001 Granted FDA Orphan Drug Designation for Mesothelioma Treatment
Avenge Bio, Inc., a leading biotech firm specializing in oncology, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AVB-001. This designation recognizes AVB-00 ...
Estimated Number of New Cancer Cases and Deaths by Sex of Respiratory system in U.S, 2022
[vc_row][vc_column][vc_custom_heading text="Estimated Number of New Cancer Cases and Deaths by Sex of Respiratory system in U.S, 2022" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][ ...
XORTX Therapeutics Secures Orphan Drug Designation for Oxypurinol to Treat Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company that aims to create new therapies to treat progressive kidney disease, is excited to announce that they have received Orphan Drug ...
FDA Grants Fast Track Designation to Bayer’s Asundexian for Stroke Prevention in Atrial Fibrillation Patients
Bayer has officially announced that the U.S. FDA has awarded Fast Track Designation to their investigational drug known as asundexian (BAY2433334). This designation recognizes its potential use as a t ...
Total Incidence Cases of Acute Respiratory Distress Syndrome (ARDS) in U.S. 2022 – 2032
[vc_row][vc_column][vc_custom_heading text="Total Incidence Cases of Acute Respiratory Distress Syndrome (ARDS) in U.S. 2022 – 2032" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/v ...
HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients
[vc_row][vc_column][vc_custom_heading text="HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_r ...
Madrigal Pharmaceuticals’ Resmetirom Receives FDA Breakthrough Therapy Designation for NASH Treatment with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA's) Breakthrough therapy designation for resmetirom in the treatment of NASH patients with liver fibrosis. The company ...
Candel Therapeutics Receives U.S. FDA Fast Track Designation for CAN-2409 to Treat Stage III/IV NSCLC Patients
Candel Therapeutics receives FDA's fast track designation for CAN-2409, a viral immunotherapy developed to improve survival in combination with valacyclovir and pembrolizumab to treat stage III/IV non ...